T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
2
A New Player in the Adjuvant Setting? GLP-1 Agonists and the Fight Against Breast Cancer Metastasis
3
AML Research Centers Around the Optimization of Available Combinations
4
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
5